Female sexual dysfunction: Therapeutic options and experimental challenges

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 4, 2009, Pages 260-269

  Allahdadi, Kyan J ^a   Tostes, Rita C A ^a,b   Webb, R Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Clitoris; Female sexual dysfunction; Pudendal arteries; Vagina

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; APOMORPHINE; ARGININE; ARGINMAX; BREMELANOTIDE; CANDOXATRILAT; CONJUGATED ESTROGEN; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; ESTROGEN; INTRENSA; NITRIC OXIDE DONOR; NMI 870; PALATIN; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SENSUA!; SILDENAFIL; TADALAFIL; TESTOSTERONE; TIBOLONE; UNCLASSIFIED DRUG; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE; YOHIMBINE;

ACNE; AGING; ATHEROSCLEROSIS; BEHAVIOR THERAPY; BLOOD FLOW; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CREAM; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DYSPAREUNIA; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; GENITAL PAIN; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; NAUSEA; NONHUMAN; PARKINSON DISEASE; REVIEW; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; TREATMENT RESPONSE; VAGINAL DRYNESS; VAGINISM; VOMITING; WORLD HEALTH ORGANIZATION; ANIMAL; DISEASE MODEL; WOMEN'S HEALTH;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; WOMEN'S HEALTH;

EID: 74049162059     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789541882     Document Type: Review

References (70)

1. Basson, R. Women's sexual function and dysfunction: current uncertainties, future directions. Int. J. Impot. Res., 2008, 20, 466.
2. Brown, A.D.; Blagg, J.; Reynolds, D.S. Designing drugs for the treatment of female sexual dysfunction. Drug Discov. Today, 2007, 12, 757.
3. Goldstein, I. Sexual dysfunction in women: what can urologists contribute? Curr. Urol. Rep., 2008, 9, 475.
4. Sommer, F.; Caspers, H.P.; Esders, K.; Klotz, T.; Engelmann, U. Measurement of vaginal and minor labial oxygen tension for the evaluation of female sexual function. J. Urol., 2001, 165, 1181.
5. Maravilla, K.R.; Yang, C.C. Magnetic resonance imaging and the female sexual response: overview of techniques, results, and future directions. J. Sex Med., 2008, 5, 1559.
6. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA, 1993, 270, 83.
7. Salonia, A.; Munarriz, R.M.; Naspro, R.; Nappi, R.E.; Briganti, A.; Chionna, R.; Federghini, F.; Mirone, V.; Rigatti, P.; Goldstein, I.; Montorsi, F. Women's sexual dysfunction: a pathophysiological review. BJU Int., 2004, 93, 1156.
8. Frank, E.; Anderson, C.; Rubinstein, D. Frequency of sexual dysfunction in "normal" couples. N. Engl. J. Med., 1978, 299, 111.
9. Laumann, E.O.; Paik, A.; Rosen, R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA, 1999, 281, 537.
10. Feldman, H.A.; Goldstein, I.; Hatzichristou, D.G.; Krane, R.J.; McKinlay, J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J. Urol., 1994, 151, 54.
11. Hatzimouratidis, K.; Hatzichristou, D. Sexual dysfunctions: classifications and definitions. J. Sex Med., 2007, 4, 241.
12. Jackson, G. Sexual dysfunction and the cardiac patient - no room for gender bias. Int. J. Clin. Pract., 1999, 53, 411.
13. Kostis, J.B.; Jackson, G.; Rosen, R.; Barrett-Connor, E.; Billups, K.; Burnett, A.L.; Carson, C., 3rd; Cheitlin, M.; Debusk, R.; Fonseca, V.; Ganz, P.; Goldstein, I.; Guay, A.; Hatzichristou, D.; Hollander, J.E.; Hutter, A.; Katz, S.; Kloner, R.A.; Mittleman, M.; Montorsi, F.; Montorsi, P.; Nehra, A.; Sadovsky, R.; Shabsigh, R. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am. J. Cardiol., 2005, 96, 85M.
14. Schwarz, E.R.; Kapur, V.; Bionat, S.; Rastogi, S.; Gupta, R.; Rosanio, S. The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. Int. J. Impot. Res., 2008, 20, 85.
15. Rosen, R.C.; Wing, R.R.; Schneider, S.; Wadden, T.A.; Foster, G.D.; West, D.S.; Kitabchi, A.E.; Brancati, F.L.; Maschak-Carey, B.J.; Bahnson, J.L.; Lewis, C.E.; Gendrano, I.N., 3rd. Erectile Dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the look AHEAD trial. J Sex Med., 2009, 6(5), 1414.
16. Fatemi, S.S.; Taghavi, S.M. Evaluation of sexual function in women with type 2 diabetes mellitus. Diab. Vasc. Dis. Res., 2009, 6, 38.
17. Olarinoye, J.; Olarinoye, A. Determinants of sexual function among women with type 2 diabetes in a Nigerian population. J. Sex Med., 2008, 5, 878.
18. Rutherford, D.; Collier, A. Sexual dysfunction in women with diabetes mellitus. Gynecol. Endocrinol., 2005, 21, 189.
19. Newman, A.S.; Bertelson, A.D. Sexual dysfunction in diabetic women. J. Behav. Med., 1986, 9, 261.
20. Giraldi, A.; Marson, L.; Nappi, R.; Pfaus, J.; Traish, A.M.; Vardi, Y.; Goldstein, I. Physiology of female sexual function: animal models. J. Sex Med., 2004, 1, 237.
21. Becker, J.B.; Rudick, C.N.; Jenkins, W.J. The role of dopamine in the nucleus accumbens and striatum during sexual behavior in the female rat. J. Neurosci., 2001, 21, 3236.
22. Jenkins, W.J.; Becker, J.B. Female rats develop conditioned place preferences for sex at their preferred interval. Horm. Behav., 2003, 43, 503.
23. Jenkins, W.J.; Becker, J.B. Role of the striatum and nucleus accumbens in paced copulatory behavior in the female rat. Behav. Brain Res., 2001, 121, 119.
24. Mermelstein, P.G.; Becker, J.B. Increased extracellular dopamine in the nucleus accumbens and striatum of the female rat during paced copulatory behavior. Behav. Neurosci., 1995, 109, 354.
25. Angulo, J.; Cuevas, P.; Cuevas, B.; Bischoff, E.; de Tejada, I.S. Antidepressant-induced inhibition of genital vascular responses is reversed by vardenafil in female rabbits. J. Sex Med., 2006, 3, 988.
26. Park, K.; Goldstein, I.; Andry, C.; Siroky, M.B.; Krane, R.J.; Azadzoi, K.M. Vasculogenic female sexual dysfunction: the hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency. Int. J. Impot. Res., 1997, 9, 27.
27. Giuliano, F.; Allard, J.; Compagnie, S.; Alexandre, L.; Droupy, S.; Bernabe, J. Vaginal physiological changes in a model of sexual arousal in anesthetized rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281, R140.
28. Allahdadi, K.J.; Tostes, R.; Webb, R.C. In Contribution of Endothelin-1 in Constriction of Pudendal Artery in Female Rats: Potential Role in Female Sexual Dysfunction, Joint Meeting of the European (ESSM) and International (ISSM) Societies for Sexual Medicine, Brussels, Belgium, Journal of Sexual Medicine; Wiley-Blackwell: Brussels, Belgium, 2008; p. 60.
29. Giraldi, A.; Persson, K.; Werkstrom, V.; Alm, P.; Wagner, G.; Andersson, K.E. Effects of diabetes on neurotransmission in rat vaginal smooth muscle. Int. J. Impot. Res., 2001, 13, 58.
30. Myung, S.C.; Lee, M.Y.; Lee, S.Y.; Yum, S.H.; Park, S.H.; Kim, S.C. Contractile changes of the clitoral cavernous smooth muscle in female rabbits with experimentally induced overactive bladder. J. Sex Med., 2008, 5, 1088.
31. Corbin, J.D. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int. J. Impot. Res., 2004, 16(Suppl. 1), S4.
32. Bryan, N.S.; Bian, K.; Murad, F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front. Biosci., 2009, 14, 1.
33. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev., 2007, 87, 315.
34. Berman, J.R.; Berman, L.A.; Lin, H.; Flaherty, E.; Lahey, N.; Goldstein, I.; Cantey-Kiser, J. Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. J. Sex Marital. Ther., 2001, 27, 411.
35. Caruso, S.; Intelisano, G.; Lupo, L.; Agnello, C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG., 2001, 108, 623.
36. Cavalcanti, A.L.; Bagnoli, V.R.; Fonseca, A.M.; Pastore, R.A.; Cardoso, E.B.; Paixao, J.S.; Soares, J.M., Jr.; Saad, F.; Baracat, E.C. Effect of sildenafil on clitoral blood flow and sexual response in postmenopausal women with orgasmic dysfunction. Int. J. Gynaecol. Obstet., 2008, 102, 115.
37. Basson, R.; McInnes, R.; Smith, M.D.; Hodgson, G.; Koppiker, N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J. Womens Health Gend. Based Med., 2002, 11, 367.
38. Uckert, S.; Oelke, M.; Albrecht, K.; Stief, C.; Jonas, U.; Hedlund, P. Immunohistochemical description of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human labia minora. J. Sex Med., 2007, 4, 602.
39. Coleman, R.A.; Smith, W.L.; Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 1994, 46, 205.
40. Fourcroy, J.L. Female sexual dysfunction: potential for pharmacotherapy. Drugs, 2003, 63, 1445.
41. Kielbasa, L.A.; Daniel, K.L. Topical alprostadil treatment of female sexual arousal disorder. Ann. Pharmacother., 2006, 40, 1369.
42. Liao, Q.; Zhang, M.; Geng, L.; Wang, X.; Song, X.; Xia, P.; Lu, T.; Lu, M.; Liu, V. Efficacy and safety of alprostadil cream for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study in chinese population. J. Sex Med., 2008, 5, 1923.
43. Pacher, P.; Mabley, J.G.; Liaudet, L.; Evgenov, O.V.; Southan, G.J.; Abdelkarim, G.E.; Szabo, C.; Salzman, A.L. Topical administration of a novel nitric oxide donor, linear polyethylenimine-nitric oxide/nucleophile adduct (DS1), selectively increases vaginal blood flow in anesthetized rats. Int. J. Impot. Res., 2003, 15, 461.
44. Evgenov, O.V.; Pacher, P.; Schmidt, P.M.; Hasko, G.; Schmidt, H.H.; Stasch, J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov., 2006, 5, 755.
45. Meston, C.M.; Worcel, M. The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder. Arch. Sex Behav., 2002, 31, 323.
46. Pfaus, J.G.; Kippin, T.E.; Coria-Avila, G. What can animal models tell us about human sexual response? Annu. Rev. Sex Res., 2003, 14, 1.
47. Ito, T.Y.; Polan, M.L.; Whipple, B.; Trant, A.S. The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status. J. Sex Marital. Ther., 2006, 32, 369.
48. Ito, T.Y.; Trant, A.S.; Polan, M.L. A double-blind placebocontrolled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J. Sex Marital. Ther., 2001, 27, 541.
49. Giraldi, A.; Alm, P.; Werkstrom, V.; Myllymaki, L.; Wagner, G.; Andersson, K. E. Morphological and functional characterization of a rat vaginal smooth muscle sphincter. Int. J. Impot. Res., 2002, 14, 271.
50. Ottesen, B.; Gerstenberg, T.; Ulrichsen, H.; Manthorpe, T.; Fahrenkrug, J.; Wagner, G. Vasoactive intestinal polypeptide (VIP) increases vaginal blood flow and inhibits uterine smooth muscle activity in women. Eur. J. Clin. Invest., 1983, 13, 321.
51. Kaye, B.; Brearley, C.J.; Cussans, N.J.; Herron, M.; Humphrey, M.J.; Mollatt, A.R. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica, 1997, 27, 1091.
52. Ziegler, D.; Witte, K.; Straub, M.; Weske, M. Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction. (WO/2005/112939). 2005. Available from http://www.wipo.int/pctdb/en/wo.jsp?wo=2005112939
53. Bancroft, J. The endocrinology of sexual arousal. J. Endocrinol., 2005, 186, 411.
54. Bancroft, J. Sexual effects of androgens in women: some theoretical considerations. Fertil. Steril., 2002, 77(Suppl. 4), S55.
55. Davis, S.R. Androgens and female sexuality. J. Gend. Specif. Med., 2000, 3, 36.
56. Rossouw, J.E.; Anderson, G.L.; Prentice, R.L.; LaCroix, A.Z.; Kooperberg, C.; Stefanick, M.L.; Jackson, R.D.; Beresford, S.A.; Howard, B.V.; Johnson, K.C.; Kotchen, J.M.; Ockene, J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, 321.
57. Braunstein, G.D.; Sundwall, D.A.; Katz, M.; Shifren, J.L.; Buster, J.E.; Simon, J.A.; Bachman, G.; Aguirre, O.A.; Lucas, J.D.; Rodenberg, C.; Buch, A.; Watts, N.B. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebocontrolled trial. Arch. Intern. Med., 2005, 165, 1582.
58. Davis, S.R.; van der Mooren, M.J.; van Lunsen, R.H.; Lopes, P.; Ribot, C.; Rees, M.; Moufarege, A.; Rodenberg, C.; Buch, A.; Purdie, D.W. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause, 2006, 13, 387.
59. Vigersky, R.A. Goldilocks and menopause. Arch. Intern. Med., 2005, 165, 1571.
60. Berman, J.R. Physiology of female sexual function and dysfunction. Int. J. Impot. Res., 2005, 17(Suppl. 1), S44.
61. Labrie, F.; Cusan, L.; Gomez, J.L.; Cote, I.; Berube, R.; Belanger, P.; Martel, C.; Labrie, C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause, 2009, 16, 30.
62. Nijland, E.A.; Weijmar Schultz, W.C.; Nathorst-Boos, J.; Helmond, F.A.; Van Lunsen, R.H.; Palacios, S.; Norman, R.J.; Mulder, R.J.; Davis, S.R. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J. Sex Med., 2008, 5, 646.
63. Dula, E.; Bukofzer, S.; Perdok, R.; George, M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur. Urol., 2001, 39, 558.
64. Giammusso, B.; Colpi, G.M.; Cormio, L.; Ludovico, G.; Soli, M.; Ponchietti, R.; Montorsi, F.; Panzironi, C.; Guastella, B. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urol. Int., 2008, 81, 409.
65. Modell, J.G.; May, R.S.; Katholi, C.R. Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study. J. Sex Marital. Ther., 2000, 26, 231.
66. Bechara, A.; Bertolino, M.V.; Casabe, A.; Fredotovich, N.A double-blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine. J. Sex Med., 2004, 1, 209.
67. Caruso, S.; Agnello, C.; Intelisano, G.; Farina, M.; Di Mari, L.; Cianci, A. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology, 2004, 63, 955.
68. Lu, W.; Jiang, W.; Chen, J.; Yin, M.; Wang, Z.; Jiang, X. Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. Int. J. Pharm., 2008, 349, 196.
69. Aughton, K.L.; Hamilton-Smith, K.; Gupta, J.; Morton, J.S.; Wayman, C.P.; Jackson, V.M. Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro. Br. J. Pharmacol., 2008, 155, 236.
70. Perelman, M.A. Clinical application of CNS-acting agents in FSD. J. Sex Med., 2007, 4(Suppl. 4), 280.